45ACTIVITIES
1ORGS REPRESENTED
69BILLS
Organizations represented
1Orgs whose LD-2 filings list John as an active lobbyist, sorted by activity volume.
Bills they file on
69S. 265824 mentions
S. 229624 mentions
S. 4314 mentions
S. 70814 mentions
S. 104014 mentions
S. 104114 mentions
S. 109514 mentions
S. 109614 mentions
S. 109714 mentions
H.R. 89014 mentions
H.R. 157414 mentions
S. 65214 mentions
S. 83214 mentions
S. 89114 mentions
S. 93214 mentions
+ 54 more bills referenced in their activities
Topics in Filings
87Policy topics John files on across all their LD-2 activities.
RESTORE Patent Rights Act×28
Big Savings Act×25
Supply chain policy×25
BIOSECURE Act×23
Most Favored Nation×23
Biopharmaceutical innovation policy×22
One Big Beautiful Bill Act×18
Inflation Reduction Act×16
Drug cost and pricing policy×16
Skinny Labels×14
Affordable Prescriptions for Patients Act×14
Stop STALLING Act×14
Show all 87 topics (+75 more) ▾
Preserve Access to Affordable Generics and Biosimilars Act×14
Interagency Patent Coordination and Improvement Act×14
Bayh-Dole march-in rights policy×14
Patent thicket policy×14
AI patent policy×14
Patent eligibility policy×14
Post-grant proceeding policy×14
Patent submission policy×14
Modernizing and Ensuring PBM Accountability×14
Accountability, and Integrity Now and for the Future×14
Vaccine policy×14
Pharmacy Benefit Manager reform×14
Drug importation policy×14
FDA policy×14
Orphan Drug Act×14
Compounding policy×14
Clinical trial policy×14
Issues 340B drug discount program policy×14
Biosimilar approval and reimbursement policy×14
Artificial intelligence policy×14
FDA Modernization×14
Medication Affordability and Patent Integrity Act×13
Biosimilar Red Tape Elimination Act×13
Stopping Pharmas Ripoffs and Drug Savings For All Act×12
Bipartisan Health Care Act×12
IRA price negotiation expansion policy×12
MAHA Commission Report×12
Make Our Children Healthy Again Competition policy×12
Issues 340B rebate pilot program Patient assistance program policy×12
Biosimilars Access and Affordability Act×12
International intellectual property and market access policy×11
Pricing and reimbursement policy×11
WTO TRIPS waiver policy×11
China outbound investment policy×11
Patent fee policy×11
PBM Price Transparency and Accountability Act×11
Mikaela Naylon Give Kids a Chance Act×11
PBM Reform×11
HELP Copays Act×11
Antimicrobial resistance policy×11
CLEAR LABELS Act×10
Most Favored Patients Act×10
FAIR ACT×10
SECURE Rx Act×10
US-UK Framework Agreement×10
Rural Development×8
User fee issues×4
Patent use codes policy×3
Give Kids a Chance Act×3
Antimicrobial resistance×3
Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×3
Res. 566: Providing for consideration of the Senate amendment to the bill×3
Science, and Related Agencies Appropriations Act, 2026×3
Accelerated approval policy×2
Competition policy×2
Patient assistance program policy×2
Drug shortages policy×2
Part D redesign and policy×2
Part B policy×2
Medicare rebate policy×2
Center for Medicare and Medicaid Innovation×2
Medicaid rebate policy×2
Protecting Patients from Deceptive Drug Ads Act×1
Innovation in Pediatric Drugs Act×1
Pandemic preparedness policy×1
Military Construction×1
Expedited Acccess to Biosimilars Act×1
MAPS Act×1
Orphan Cures Act×1
Prescription Information Modernization×1
Insulin policy×1
Medicaid waiver policy×1
MVP Act×1
Legislative Branch×1
Open Payments Expansion Act×1
Issue mix
LDA general-issue codes weighted by activity count.
Copyright/Patent/Trademark14
Health Issues14
Trade (domestic/foreign)11
Budget/Appropriations4
Medicare/Medicaid2